Evidence map›Paper›PMID 31176716›Full record

ReviewNeurobiology of disease2020

Tetramethylenedisulfotetramine neurotoxicity: What have we learned in the past 70 years?

Marcela Lauková, Jana Velíšková, Libor Velíšek, Michael P Shakarjian

Open access · hybridAbstract readReview
In one paragraph

Review in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. The efficacy of γ-aminobutyric acid type A receptor (GABAToxicology and applied pharmacology · 2021
    Article
  3. Article
  4. Special issue: emerging chemical terrorism threats.Toxicology mechanisms and methods · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Marcela LaukováDepartment of Public Health, Division of Environmental Health Science, School of Health Sciences and Practice, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Pediatrics, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, Bratislava 84505, Slovakia.
Jana VelíškováDepartment of Cell Biology and Anatomy, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Obstetrics and Gynecology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Neurology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA.
Libor VelíšekDepartment of Cell Biology and Anatomy, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Neurology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Pediatrics, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA.
Michael P ShakarjianDepartment of Public Health, Division of Environmental Health Science, School of Health Sciences and Practice, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Cell Biology and Anatomy, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, USA; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Rutgers-Robert Wood Johnson Medical School, 675 Hoes Ln W, Piscataway, NJ 08854, USA. Electronic address: michael_shakarjian@nymc.edu.
New York Medical College · USRutgers, The State University of New Jersey · USSlovak Academy of Sciences · SK

Funding

Importance of Pannexin to Astrocyte and Neuronal ATPR01NS092786 · NINDS · NEW YORK MEDICAL COLLEGE · PI SCEMES, ELIANA, VELISKOVA, JANA · 2016 to 2019
$2.3M
Developing and Evaluating Countermeasures Against TetramethylenedisulfotetramineR21NS084900 · NINDS · NEW YORK MEDICAL COLLEGE · PI SHAKARJIAN, MICHAEL PETER · 2014 to 2015
$805k
NINDS NIH HHS R01 NS092786NINDS NIH HHS R21 NS084900
6 · The paper itself

Abstract

Tetramethylenedisulfotetramine (tetramine, TETS, TMDT) is a seizure-producing neurotoxic chemical formed by the condensation of sulfamide and formaldehyde. Serendipitously discovered through an occupational exposure in 1949, it was promoted as a rodenticide but later banned worldwide due to its danger to human health. However, exceptional activity of the agent against rodent pests resulted in its clandestine manufacture with large numbers of inadvertent, intentional, and mass poisonings, which continue to this day. Facile synthesis, extreme potency, persistence, lack of odor, color, and taste identify it as an effective food adulterant and potential chemical agent of terror. No known antidote or targeted treatment is currently available. In this review we examine the origins of tetramethylenedisulfotetramine, from its identification as a neurotoxicant 70 years ago, through early research, to the most recent findings including the risk it poses in the post-911 world. Included is the information known regarding its in vitro pharmacology as a GABA

Indexed as

AnimalsBridged-Ring CompoundsGABA-A Receptor AntagonistsHumansNeurotoxicity SyndromesRodenticidesSeizuresBridged-Ring CompoundsGABA-A Receptor AntagonistsRodenticidestetramethylenedisulfotetramineCountermeasuresNeurotoxicologyPharmacotherapySeizuresTerrorismTetramethylenedisulfotetramineVulnerable populations

Identifiers

PMID31176716
PMCPMC6895414
OpenAlexW2950541434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.